The vaccine from Pfizer-BioNTech a week or more after the second dose is 95.3% effective against coronavirus infection. Updated estimates of the effectiveness of a biological product in the fight against the COVID-19 epidemic in Israel were published by The Lancet.
The authors used surveillance data from the first four months of the national vaccination campaign for people 16 years and older to identify isolated cases of laboratory-confirmed SARS-CoV-2 infections and their outcomes.
From January 24 to April 3, 2021, the country recorded 232,268 cases of infection, 7694 hospitalizations, 4481 severe or critical hospitalizations, as well as 1,113 deaths from COVID-19. As of April 3, more than 4.7 million (72%) of ~ 6.5 million people aged 16 and over were fully immunized (received two doses).
Read Also: How Pfizer-BioNTech Vaccine Protects Elderly Against Dangerous COVID-19 Cases: Report
The vaccine protected 91.5% from the asymptomatic course of covid and exactly 97% from the disease with symptoms.
Complete immunization with the drug gave 97.2% protection against hospitalizations and 97.5% against severe / critical cases with hospitalization.
The vaccine protected 96.7% from deaths, the study authors emphasized.
They write that the two doses of the vaccine are highly effective in all ages ≥16 years (including the oldest ≥85 years) in preventing asymptomatic infection, symptomatic illness, hospitalizations, severe cases and death, including those caused by the “UK” variant of the virus.
Scientists have estimated the prevalence of this strain in Israel at 94.5% of all cases during the period mentioned above.
“In all age groups, as vaccination coverage has increased, the rate of SARS-CoV-2 outcomes has decreased. Evidence suggests that vaccination can help control the pandemic,” the authors of the publication emphasized.
Open tables:
→ number of fully immunized as of April 3;
→ the effectiveness of two doses 7 days after the second;
→ the effectiveness of two doses 7 days after the second in the oldest;
→ the effectiveness of two doses 14 days after the second;
→ graphs of the decline in epidemic indicators by age.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
